Member Info for Timster

I'm only questioning it as these patients on the trial are end of life, would have had several cycles of chemo pre trial(I'd guess), so would likely have lost their hair already.

Was AS saying patients receiving AVA6000 won't lose their hair, which I always thought was a given as dox is confined to the tumour and doesn't damage the rest of your body.
Or was he saying the existing trial patients hadn't lost their hair after receiving AVA6000 dosing?

Just not picking :)

Semantics perhaps but he said
I asked him to confirm that patients who are given AVA6000 won't lose their hair and he confirmed it

Not:
I asked him to confirm that patients who are given AVA6000 hadn't lost their hair and he confirmed it

If it works of course that would be true, chemo without the side effects

Mates rates

A sell that caused the price to increase, interesting....

Checked out wynbores history and hated on every board he posts. Very strange character

Are you a double glazing sales man wynbore?
I can imagine you in people's houses for 6hrs refusing to leave while you break them down with a boring lengthy sales pitch and fantasy stories about how great you and your product are.

Until eventually they crack, or die of boredom.

Worth remembering what's due in the coming months

AVA6000 Phase I dose escalation data
Biopsy data AVA6000 Doxorubicin & FAP
Modelled pK Doxorubicin data
MTD (if reached)/RP2D selected

Dose escalation already occurred in cohort 3

Spot on...

I'm shocked, he responds with a boring essay that says nothing (although I only read the first line)

Absolutely the drop is not for any material reason as all recent RNSs have been positive.

Just annoying that it's making the twats shorting money...

If posts could be pinned this would be at the top as a wynbore public warning announcement.

Data due late Q3 so lots of SP messing to go....

There is no need to complete the remainder of this form In the case of fee-for-service we have a strategic alliance with Avacta Ltd. We will pass on your details and they will contact you to discuss your requirements.

Lots of Avacta references on Leeds evaluation form
"6. For any commercialisation, the intellectual property associated with Affimer reagents is owned by the University of Leeds and licensed to Avacta Life Sciences Ltd and so is subject to initial notification of The University of Leeds Commercialisation Services (contact Dr Chris Brown, IP & Commercialisation Manager "

https://biologicalsciences.leeds.ac.uk/downloads/download/54/project_evaluation_form_for_affimers

It's this
https://clinicaltrials.gov/ct2/show/NCT03973333

Rorkesdrift posted earlier

Discussed earlier and on another report it says

" an experimental medicine combined with Atezolizumab, an immunotherapy drug administered intravenously which she continues to have every three weeks"

Not us, but might be one day

Must be lies, or the whole market is crap.

Wynbore will send an essay now, one moment

Nice write up